Reagent update
Current availability from MHRA of candidate influenza vaccine viruses, SRD reagents and neuraminidase reagents for use in the 2024-25 Northern hemisphere season and 2024 Southern hemisphere season (See below for pricing information)
More information can be found in the Influenza Resource Centre pages
Update 160 29 February 2024
Candidate influenza viruses for use in the Southern hemisphere 20241
Candidate influenza vaccine viruses
|
NIBSC code
|
|
H1N1
|
|
|
A/Victoria/4897/2022
|
23/252
|
|
IVR-238 reassortant derived from A/Victoria/4897/2022
|
23/250
|
|
A/Norway/31694/2022
|
22/312
|
|
NIB-133 reassortant derived from A/Norway/31694/2022
|
23/112
|
NIB-134 reassortant derived from A/Catalonia/NSVH161512065/2022)
|
23/126 |
|
A/Wisconsin/67/2022
|
23/120
|
|
A/West Virginia/30/2022
|
23/122
|
|
CNIC-2301 reassortant derived from A/Sichuan-Qingyang/SWL1148/2023
|
23/214 |
|
H3N2
|
|
|
A/Thailand/8/2022
|
23/204
|
|
IVR-237 reassortant derived from A/Thailand/8/2022
|
23/206
|
|
A/California/122/2022
|
23/200
|
|
A/Brandenburg/15/2022
|
23/202
|
|
A/Brisbane/837/2022
|
23/216
|
IVR-246 (A/Brisbane/837/2022)
|
23/238 |
|
B (Victoria lineage)
|
|
|
B/Austria/1359417/2021
|
23/228
|
|
BVR-26 reassortant derived from B/Austria/1359417/2021
|
21/218
|
|
B/Michigan/01/2021
|
21/244
|
|
B/Singapore/WUH4618/2021
|
21/242
|
|
B/Guangdong-Zhenjiang/1516/2021
|
21/388
|
1Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season (who.int)
2 Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season (who.int)
SRD reagents for use in the Southern hemisphere 2024
1 and Northern Hemisphere 2024-252
Reagents for influenza vaccine standardisation
|
NIBSC code
|
|
H1N1
|
|
|
A/Victoria/4897/2022 (IVR-238) antigen
|
22/320
|
|
A/Victoria/4897/2022 - like antiserum
|
23/100
|
|
H3N2
|
|
|
A/Thailand/8/2022 (IVR-237) antigen
|
23/220
|
|
A/California/122/2022 (SAN-022) antigen
|
23/226
|
|
A/Thailand/8/2022 – like antiserum
|
23/222
|
|
|
|
B (Victoria lineage)
|
|
|
B/Austria/1359417/2021 (BVR-26) antigen
|
21/316
|
|
B/Singapore/WUH4618/2021 (cell derived) antigen
|
23/268 |
|
B/Michigan/01/2021 antigen
|
21/330
|
| B/Singapore/WUH4618/2021 (cell derived) antigen |
23/268 |
|
B/Austria/1359417/2021 - like antiserum
|
21/326
|
|
B (Yamagata lineage)
|
|
|
B/Phuket/3073/2013 antigen
|
21/136
|
|
B/Utah/9/2014 (cell derived) antigen
|
15/100
|
|
B/Singapore/INFTT-16-0610/2016 (cell derived) antigen
|
19/308
|
|
B/Phuket/3073/2013 - like antiserum
|
22/132
|
1 Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season (who.int)
2 Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season (who.int)
Neuraminidase reagents
|
NIBSC code
|
|
N1
|
|
|
NA antiserum prepared from A/California/7/2009
|
10/218
|
|
NA antiserum prepared from A/New Caledonia/20/99
|
04/230
|
| NA antiserum prepared from A/Victoria/4897/2022 |
23/208 |
|
N2
|
|
|
NA antiserum prepared from A/Victoria/361/2011
|
14/144
|
|
NA antiserum prepared from A/South Australia/34/2019
|
19/320
|
|
B
|
|
|
NA antiserum prepared from B/Jiangsu/10/2003
|
04/228
|
|
NA antiserum prepared from B/Malaysia/2506/2004
|
05/252
|
|
NA antiserum prepared for B/Florida/4/2006
|
09/316 (please contact for availability)
|
|
NA antiserum prepared from B/Phuket/3073/2013
|
21/322
|
Access To B/Yamagata lineage viruses is currently restricted.
Please contact Othmar.Engelhardt@mhra.gov.uk and Jason.Long@mhra.gov.uk
Pricing information
Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to a handling fee as stated on the product information page, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the handling fee.
Calibration of Reagents for Influenza vaccine standardisation
Reference antigens and antiserum reagents for the standardization of vaccines are produced by the following WHO laboratories:
Essential Regulatory Laboratories (ERL)
Medicines and Healthcare products Regulatory Agency (MHRA), UK
Center for Biologics Evaluation and Research (CBER), USA
National Institute for Infectious Disease (NIID), Japan
Therapeutic Goods Administration (TGA), Australia